share_log

bluebird bio | 4: Statement of changes in beneficial ownership of securities-Officer Colvin Richard A

bluebird bio | 4: Statement of changes in beneficial ownership of securities-Officer Colvin Richard A

bluebird bio | 4：持股變動聲明-高管 Colvin Richard A
美股SEC公告 ·  2024/10/03 04:12

牛牛AI助理已提取核心訊息

On September 30, 2024, Richard A Colvin, the Chief Medical Officer of bluebird bio, Inc. [BLUE], completed a transaction acquiring 50,000 shares of the company's common stock at no cost. This grant of shares has increased Colvin's direct holdings in the company to a total of 168,368 shares. The transaction, which was a grant rather than a purchase on the open market, reflects the company's compensation or incentive strategy for its executives. The shares were granted directly to Colvin, emphasizing his vested interest in the company's performance.
On September 30, 2024, Richard A Colvin, the Chief Medical Officer of bluebird bio, Inc. [BLUE], completed a transaction acquiring 50,000 shares of the company's common stock at no cost. This grant of shares has increased Colvin's direct holdings in the company to a total of 168,368 shares. The transaction, which was a grant rather than a purchase on the open market, reflects the company's compensation or incentive strategy for its executives. The shares were granted directly to Colvin, emphasizing his vested interest in the company's performance.
2024年9月30日，bluebird bio, Inc. [BLUE]的首席醫療官Richard A Colvin完成了一項交易，獲得了公司的50,000股普通股，無需支付費用。這批股份的授予使Colvin在該公司的直接持股總數增至168,368股。這筆交易是一次授予，而不是在公開市場上購買，反映了公司對其高管的補償或激勵策略。這些股份直接授予Colvin，突顯了他對公司績效的既得利益。
2024年9月30日，bluebird bio, Inc. [BLUE]的首席醫療官Richard A Colvin完成了一項交易，獲得了公司的50,000股普通股，無需支付費用。這批股份的授予使Colvin在該公司的直接持股總數增至168,368股。這筆交易是一次授予，而不是在公開市場上購買，反映了公司對其高管的補償或激勵策略。這些股份直接授予Colvin，突顯了他對公司績效的既得利益。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間